Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494055 | 0.86 | MEN1 (0.40) | TDP1DPP4DPP7OPRD1OPRM1 | |
| SCHEMBL3919530 | 0.80 | MEN1 (0.50) | OPRD1OPRM1OPRK1OPRL1MEN1 | |
| SCHEMBL224088 | 0.76 | TDP1 (0.32) | TDP1DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL6541247 | 0.74 | MEN1 (0.42) | TDP1SLC6A2SLC6A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6540416 | 0.74 | MEN1 (0.42) | TDP1SLC6A2SLC6A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6540563 | 0.74 | MEN1 (0.42) | TDP1SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL5683229 | 0.74 | OPRM1 (0.40) | TDP1OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL7110894 | 0.74 | TDP1 (0.35) | TDP1DPP4DPP7OPRD1SLC6A2 | |
| SCHEMBL3095736 | 0.73 | DPP4 (0.38) | TDP1DPP4 | |
| SCHEMBL28960292 | 0.72 | MEN1 (0.43) | TDP1OPRD1SLC6A2SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | TDP1 2914/4885DPP4 1852/4885DPP7 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.